1.
Stephan P, Chohan KL, Redd RA, Dixon W, Zou A, Ahmed S, Flowers CR, Chauhan A, Ayers AA, Shouse G, Thiruvengadam SK, Herrera AF, Bock AM, Epperla N, Lunning MA, Salles G, Falchi L, Sawalha Y, Godbole S, Jallouk AP, Bhaskar ST, Major A, Bair SM, Rodig SJ, Armand P, Merryman RW, Danilov AV, Crombie JL. Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma. Haematologica [Internet]. 2026Nov.19 [cited 2026Nov.22];. Available from: https://haematologica.org/article/view/14552